Fox Chase Cancer Center News

PHILADELPHIA (February 14, 2022)—Data from researchers at Fox Chase Cancer Center indicates that advanced kidney cancer patients treated with a combination of nivolumab and axitinib experienced similar therapeutic benefits to those patients treated with other drug combinations with similar safety profiles. The new research was presented at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, which is being held February 17-19.

PHILADELPHIA (February 11, 2022)—Fox Chase Cancer Center has been awarded a Research Education Program grant that will allow the center to expand the reach of its University of Delaware-Fox Chase Cancer Center Summer Research Fellowship.

PHILADELPHIA (February 10, 2022)—Johnathan R. Whetstine, PhD, director of the Cancer Epigenetics Institute at Fox Chase Cancer Center, was recently honored with a Maximizing Investigators’ Research Award (MIRA) from the National Institute of General Medical Sciences (NIGMS). This five-year grant will fund fundamental research on DNA amplification and uncovering pathways that control it.

PHILADELPHIA (February 7, 2022)—According to a new study from researchers at Fox Chase Cancer Center, mRNA vaccine for COVID-19 is just as safe for people with cancer as it is for cancer-free individuals.

PHILADELPHIA (February 3, 2022)—Linda Fleisher, PhD, MPH, associate research professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, was recently recognized with the Lillie D. Shockney Lifetime Achievement Award from the Academy of Oncology Nurse & Patient Navigators (AONN+).

PHILADELPHIA (February 1, 2022)—Patients recovering from COVID-19 who continue to have certain debilitating symptoms such as chronic fatigue may need long-term support, including evaluation of the endocrine system, according to a recent review.

PHILADELPHIA (February 1, 2022)—In a recent study, researchers at Fox Chase Cancer Center found that gene therapy using a genetically engineered viral vector was highly effective in treating cystathionine β-synthase deficiency (CBS) in mice.

PHILADELPHIA (January 31, 2022)—Margaret von Mehren, MD, chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new vice chair of the Department of Hematology/Oncology.